True it is new territory for this company having that revenue line attributing to sales which is great. Very high cost though which was surprising... they have a lot of recently employed execs in this quarterly i skimmed through and feel this is an over management issue always happens... "reduction in costs" line will come in the next few months no doubt...
Finding it all just a bit meh for now with so many good opportunities in the market..
- Forums
- ASX - By Stock
- FFX
- Ann: Quarterly Activities Report
Ann: Quarterly Activities Report, page-43
-
-
- There are more pages in this discussion • 250 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FFX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online